Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Blueprint for Patient Input in Medtech Device Development

Device Development Blueprint: Guidance for Early and Systematic Patient Involvement in Medical Device Development
 

Source
Patient Engagement Synapse

Link
Device Development Blueprint: Guidance for Early and Systematic Patient Involvement in Medical Device Development
 

Description of Case Study

Boehringer Ingelheim, working with Savvy Cooperative and a group of patients, patient advocates, health-care providers, and industry professionals, cocreated a “Device Development Blueprint.” This framework helps medical device developers integrate patient perspectives throughout the device development process. The stated purpose was to move device teams away from ad hoc or late-stage patient input toward a systematic model: a five-stage road map (Foundational Understandings; Exploring Possible Options; Exploring Chosen Option; Refining Selected Prototype; Post-Release Feedback) with defined stakeholders, engagement methods, and feedback loops at each stage.

The guide outlines when and how to engage patients across key development stages and provides practical considerations related to device usability, accessibility, personalization, packaging, educational materials, and other factors that influence the patient experience.

Designed for use across therapeutic areas and device types, the blueprint offers a structured approach for incorporating patient insights early and continuously, ensuring products are developed with a deeper understanding of user needs, preferences, and real-world challenges.
 

Quick Facts

Organization name: Boehringer Ingelheim
Organization type: large medtech company (250+ employees)
Product category: medical device
Region(s) of patient engagement activities: not specified
Total product life cycle stage(s): discovery/preclinical; clinical/testing;
evaluation/authorization; coverage/payment; adoption; post-approval
surveillance/monitoring

 

Product Type(s)

medical device:

  • therapeutic devices
     

Product Medical Specialty Area(s)

  • Other: respiratory
     

Stakeholders

  • medtech company: internal discovery/research and development teams
  • medtech company: internal marketing teams
  • patients and caregivers, patient organizations
  • providers (clinicians, hospital/health system administrators)
     

Methods and Sources of Patient Input

  • interviews/focus groups/surveys
  • patient preference information/studies
  • other: human factors/usability testing
  • other: ethnography
  • other: workshops
     

Impact of Patient Engagement

Patient involvement directly shaped the content and structure of the blueprint by identifying the factors that matter most to people who use medical devices. Through cocreation with patients and patient organization representatives, the guidance expanded beyond device functionality to address areas such as usability, accessibility, personalization, education, packaging, language, and sustainability.

The resulting framework was integrated into Boehringer Ingelheim’s corporate device development processes, providing a standardized approach for incorporating patient perspectives throughout device development. According to the case study, use of the blueprint has already facilitated engagement with patients and helped uncover considerations that were critical to patient-centered device design in ongoing development projects.
 

Lessons Learned

  • Pursue early and continuous involvement across the development life cycle: Patient involvement is most effective when it occurs early and continuously throughout device development rather than being limited to isolated feedback activities. Cocreation offers patients the chance to provide valuable insights across multiple aspects of development, including device design, usability, education, packaging, accessibility, and implementation.
  • Encourage shared decision-making between patients and developers: Additionally, patients and developers are most successful when they work as partners with shared decision-making responsibilities. Bringing patients, patient advocates, and device developers together helped identify priorities that may otherwise have been overlooked.
  • Tie engagement to an indication or platform strategy, not a single asset: The blueprint is explicitly recommended for asset-independent use to maximize synergies across multiple projects within or across indications instead of running a separate engagement per product.
  • Match method rigor to the stage of development: Certain stages favor qualitative methods (interviews, ethnography, asynchronous workshops) to build foundational understanding, while other stages shift toward more structured methods (preference/Delphi surveys, human factors/usability testing, satisfaction questionnaires) as options narrow toward one design option or approach.
  • Don’t assume prelaunch testing catches everything: Post-release engagement is justified specifically because it “could highlight anything that may have been missed during the development process”; that is, it is treated as a distinct, necessary opportunity to gather patient input rather than a formality after product development is done.